Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Phillips

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
CNS Drugs|May 4, 2019
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant EpilepsyJames W Wheless, Dennis Dlugos, Ian Miller, et al.
Expert Review of Anti-Infective Therapy|December 8, 2004
Evidence-based guidelines for the management of Lyme diseaseDaniel Cameron, Andrea Gaito, Nick Harris, et al.
Epilepsia|February 2, 2026
Characterizing early behavioral and social-emotional problems in young children with SCN1A+ Dravet syndrome: Findings from the ENVISION prospective natural history studyIngrid E Scheffer, M Scott Perry, Joseph Sullivan, et al.
Epilepsia|November 18, 2025
Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history studyJoseph Sullivan, M Scott Perry, Ingrid E Scheffer, et al.
Epilepsia|December 4, 2023
Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history studyM Scott Perry, Ingrid E Scheffer, Joseph Sullivan, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
CNS Drugs|May 4, 2019
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant EpilepsyJames W Wheless, Dennis Dlugos, Ian Miller, et al.
Expert Review of Anti-Infective Therapy|December 8, 2004
Evidence-based guidelines for the management of Lyme diseaseDaniel Cameron, Andrea Gaito, Nick Harris, et al.
Epilepsia|February 2, 2026
Characterizing early behavioral and social-emotional problems in young children with SCN1A+ Dravet syndrome: Findings from the ENVISION prospective natural history studyIngrid E Scheffer, M Scott Perry, Joseph Sullivan, et al.
Epilepsia|November 18, 2025
Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history studyJoseph Sullivan, M Scott Perry, Ingrid E Scheffer, et al.
Epilepsia|December 4, 2023
Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history studyM Scott Perry, Ingrid E Scheffer, Joseph Sullivan, et al.
Pageof 6